DRMA
Dermata Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.21 / 10
Netural
Capital flows are rated good (7.67/10), with Small-inflow trend positive and other scales negative. Analyst coverage is limited to one provider with a Strong Buy rating, but historical win rate is only 50%. This sparse, neutral-to-positive sentiment contrasts with the otherwise weak technical and fundamental backdrop.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-08-21
InstitutionMaxim Group
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for DRMA?
- DRMA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.21/10 (Netural).
